Inventor
MANNICK JOAN
US21 patents
⚠️ This page may combine multiple inventors who share the name “MANNICK JOAN”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
NOVARTIS AG
14 patentsUS10174095B2Jan 8, 2019
Nucleic acid encoding a humanized anti-BCMA chimeric antigen receptor
NOVARTIS AG41 citations96
US11084880B2Aug 10, 2021
Anti-BCMA chimeric antigen receptor
NOVARTIS AG15 citations93
US10287354B2May 14, 2019
Regulatable chimeric antigen receptor
NOVARTIS AG29 citations92
US10286069B2May 14, 2019
Low, immune enhancing, dose MTOR inhibitors and uses thereof
NOVARTIS AG8 citations83
US10004803B2Jun 26, 2018
Low, immune enhancing, dose mtor inhibitors and uses thereof
NOVARTIS AG13 citations83
US10774388B2Sep 15, 2020
Biomarkers predictive of therapeutic responsiveness to chimeric antigen receptor therapy and uses thereof
NOVARTIS AG7 citations80
US10568947B2Feb 25, 2020
Treatment of cancer using a CLL-1 chimeric antigen receptor
NOVARTIS AG6 citations71
US10441584B2Oct 15, 2019
Methods of enhancing immune response
NOVARTIS AG2 citations68
US11591404B2Feb 28, 2023
Treatment of cancer using a CD123 chimeric antigen receptor
NOVARTIS AG0 citations62
US10703819B2Jul 7, 2020
Treatment of cancer using a CD123 chimeric antigen receptor
NOVARTIS AG1 citations62
US11578130B2Feb 14, 2023
Regulatable chimeric antigen receptor
NOVARTIS AG1 citations61
US11459390B2Oct 4, 2022
Phosphoglycerate kinase 1 (PGK) promoters and methods of use for expressing chimeric antigen receptor
NOVARTIS AG0 citations61
US11045463B2Jun 29, 2021
Methods of enhancing immune response
NOVARTIS AG0 citations58
US10993940B2May 4, 2021
Methods of enhancing immune response
NOVARTIS AG0 citations58